Free Trial
NASDAQ:IOVA

Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

Iovance Biotherapeutics logo
$5.91 +0.15 (+2.60%)
As of 01/17/2025 04:00 PM Eastern

About Iovance Biotherapeutics Stock (NASDAQ:IOVA)

Key Stats

Today's Range
$5.79
$6.00
50-Day Range
$5.76
$9.69
52-Week Range
$5.62
$18.33
Volume
6.55 million shs
Average Volume
6.07 million shs
Market Capitalization
$1.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
Consensus Rating
Moderate Buy

Company Overview

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
83rd Percentile Overall Score

IOVA MarketRank™: 

Iovance Biotherapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 191st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Iovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Iovance Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Iovance Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.23) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Iovance Biotherapeutics is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Iovance Biotherapeutics is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Iovance Biotherapeutics has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Iovance Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    24.82% of the float of Iovance Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Iovance Biotherapeutics has a short interest ratio ("days to cover") of 8.9.
  • Change versus previous month

    Short interest in Iovance Biotherapeutics has recently increased by 3.34%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Iovance Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Iovance Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.82% of the float of Iovance Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Iovance Biotherapeutics has a short interest ratio ("days to cover") of 8.9.
  • Change versus previous month

    Short interest in Iovance Biotherapeutics has recently increased by 3.34%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Iovance Biotherapeutics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Iovance Biotherapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    40 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • MarketBeat Follows

    28 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Iovance Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $503,000.00 in company stock.

  • Percentage Held by Insiders

    12.10% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Iovance Biotherapeutics' insider trading history.
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

3 Stocks That Could Turn $1,000 Into $5,000 by 2030
Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Wells Fargo Remains a Buy on Iovance Biotherapeutics (IOVA)
Wells Fargo Remains a Buy on Iovance Biotherapeutics (IOVA)
See More Headlines

IOVA Stock Analysis - Frequently Asked Questions

Iovance Biotherapeutics' stock was trading at $7.40 at the beginning of the year. Since then, IOVA shares have decreased by 20.1% and is now trading at $5.91.
View the best growth stocks for 2025 here
.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. The biotechnology company had revenue of $58.56 million for the quarter, compared to the consensus estimate of $53.54 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative trailing twelve-month return on equity of 58.43%.

Top institutional shareholders of Iovance Biotherapeutics include Assenagon Asset Management S.A. (0.57%), Hennion & Walsh Asset Management Inc. (0.11%), SG Americas Securities LLC (0.02%) and Clear Harbor Asset Management LLC (0.01%). Insiders that own company stock include Wayne P Rothbaum, Merrill A Mcpeak, Iain D Dukes, Ryan D Maynard and Frederick G Vogt.
View institutional ownership trends
.

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/07/2024
Today
1/20/2025
Next Earnings (Estimated)
2/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
500
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$34.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+289.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-444,040,000.00
Net Margins
-451.25%
Pretax Margin
-458.01%

Debt

Sales & Book Value

Annual Sales
$90.86 million
Book Value
$2.28 per share

Miscellaneous

Free Float
267,902,000
Market Cap
$1.80 billion
Optionable
Optionable
Beta
0.57

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:IOVA) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners